Marksans Pharma Share Price Gains Nearly 2% After US FDA Clears Goa Plant With Zero Observations

Mumbai, November 10, 2025: Shares of Marksans Pharma Ltd (NSE: MARKSANS, BSE: 524404) gained nearly 2% on Monday after the company announced a positive outcome from a recent inspection conducted by the US Food and Drug Administration (US FDA).

Marksans Pharma Limited is engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations. The company is headquartered in Mumbai and operates across global markets. The company is listed on NSE and BSE and trades under the tickers MARKSANS and 524404, respectively.

Details of the Inspection

Marksans Pharma reported that the current Good Manufacturing Practice (cGMP) inspection at its second manufacturing facility in Verna Industrial Estate, Goa, was completed successfully. The inspection was carried out by the US FDA from November 3 to November 7, 2025, and concluded without any Form 483 observations, reflecting the company’s strong adherence to international quality and compliance standards.

Commenting on the development, Mr. Mark Saldanha, Managing Director of Marksans Pharma, said, “The successful outcome of the cGMP inspection by the US FDA is a testament to our ongoing commitment to product quality and regulatory compliance.”

Market Snapshot

The share price of Marksans Pharma Limited was trading at ₹186.48 as of November 10, 2025, 3:29 pm. This was a 1.93% or ₹3.53 rise from its previous close of ₹182.95. The intraday range was between ₹182.99 and ₹189.09. The company had a positive trading session today. Its total market capitalisation stood at ₹8,479.15 crore. Further, it had a total traded value and volume of ₹23.95 crore and 12.85 lakh shares, respectively.

REF: https://nsearchives.nseindia.com/corporate/MARKSANS_10112025121905_SEIntimation.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations